Company · LLY
Eli Lilly
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
91
40 still marketed
Novel approvals
44
Approvals since 2021
58
Originals and new uses
Phase 3 trials
559
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Olumiant new use Oct 9, 2026
- Jaypirca new use OrphanOct 2, 2026
- Olumiant new use Sep 25, 2026
- Onswik approved NovelSep 23, 2026
- Verzenio new use Sep 18, 2026
- Inluriyo new use Sep 18, 2026
- Mounjaro new use Aug 27, 2026
- Mounjaro new use Aug 27, 2026
- Zepbound new use Aug 26, 2026
- Retevmo new use OrphanJul 14, 2026
Drugs in development (32)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- BrenipatideLY3537031Phase 313 trials
Eli Lilly · Alcohol Use Disorder, Irritable Bowel Syndrome, Depressive Disorder, Major
- EloralintideLY3841136Phase 313 trials
Eli Lilly · Obesity, Overweight, Diabetes Mellitus, Type 2
- OlomorasibLY3537982Phase 36 trials
Eli Lilly · Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Neoplasm Metastasis
- MazdutideLY3305677Phase 35 trials
Eli Lilly · Type 2 Diabetes, Obesity, Overweight
- MibavademabREGN4461Phase 35 trials
Regeneron · Generalized Lipodystrophy, Functional Hypothalamic Amenorrhea, FHA
- TersolisibLY4064809, STX-478Phase 33 trials
Eli Lilly · Breast Neoplasms, Neoplasm Metastasis, Breast Cancer
- ClazakizumabLY5724886, CSL300Phase 32 trials
Eli Lilly · Atherosclerosis, Cardiovascular Disease, Obesity
- LepodisiranLY3819469Phase 32 trials
Eli Lilly · Atherosclerosis, Cardiovascular Diseases, Lipoprotein(a)
- VepugratinibLY3866288Phase 32 trials
Eli Lilly · Urinary Bladder Neoplasms, Urologic Neoplasms, Receptor, Fibroblast Growth Factor, Type 3
- RemternetugLY3372993Phase 31 trial
Eli Lilly · Alzheimer's Disease
- MORF-057zotemtegrast, LY4268989Phase 24 trials
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) · Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis (UC)
- LY4065967Phase 23 trials
Eli Lilly · Chronic Pain, Diabetic Peripheral Neuropathic Pain, Osteoarthritis, Knee
- MacupatideLY3532226Phase 23 trials
Eli Lilly · Obesity, Overweight, Diabetes Mellitus, Type 2
- BimagrumabLY3985863, BYM338Phase 22 trials
Eli Lilly · Heart Failure, Diastolic, Diastolic Heart Failure, Heart Failure, Normal Ejection Fraction
- EltrekibartLY3041658Phase 22 trials
Eli Lilly · Ulcerative Colitis, Ulcerative Colitis Chronic, Hidradenitis Suppurativa
- LY188011Phase 22 trials
Eli Lilly · Neoplasms, Child, Adolescent
- LY3549492Phase 22 trials
Eli Lilly · Obesity, Overweight
- LY4005130Phase 22 trials
Eli Lilly · Alopecia Areata, Vitiligo, Non-Segmental Vitiligo (NSV)
- LY4395089Phase 22 trials
Eli Lilly · Crohn Disease, Colitis, Ulcerative
- LY2784544Phase 21 trial
Eli Lilly · Neoplasms, Hematologic
- LY3457263Phase 21 trial
Eli Lilly · Type 2 Diabetes
- LY3537021Phase 21 trial
Eli Lilly · Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions
- LY3848575Phase 21 trial
Eli Lilly · Neuropathic Pain, Distal Sensory Polyneuropathy
- LY3871801Phase 21 trial
Eli Lilly · Rheumatoid Arthritis
Recruiting Phase 3 trials
Largest first.
- Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)Pivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07157774 · 10,450 participants (planned) · Start Sep 2, 2025 · Primary completion Mar 2031
Drug: Muvalaplin; Placebo · For: Elevated Lp(a); Atherosclerotic Cardiovascular Disease (ASCVD)
Sites: Birmingham, Alabama; Apache Junction, Arizona; Gilbert, Arizona · 804 sites in all
- A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)Pivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07241390 · 7,140 participants (planned) · Start Dec 1, 2025 · Primary completion Aug 2031
Drug: Orforglipron; Placebo · For: Atherosclerosis Cardiovascular Disease; Chronic Kidney Disease
Sites: Bahía Blanca, Argentina; Buenos Aires, Argentina; C.a.b.a., Argentina · 566 sites in all
- A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)Pivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07165028 · 4,500 participants (planned) · Start Oct 15, 2025 · Primary completion Aug 2030
Drug: Tirzepatide; Retatrutide and 1 more · For: Metabolic Dysfunction-Associated Steatotic Liver Disease
Sites: Tuscaloosa, Alabama; Chandler, Arizona; Gilbert, Arizona · 563 sites in all
- A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 ObesityPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07794579 · 2,001 participants (planned) · Start Aug 26, 2026 · Primary completion Aug 2029
Drug: Orforglipron; Placebo · For: Overweight; Prediabetic State; Prehypertension and 1 more
Sites: Anniston, Alabama; Birmingham, Alabama; Pelham, Alabama · 180 sites in all
- A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 DiabetesPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07321886 · 1,980 participants (planned) · Start Feb 6, 2026 · Primary completion Mar 2028
Drug: Eloralintide; Placebo · For: Obesity; Overweight
Sites: Tuscaloosa, Alabama; Scottsdale, Arizona; Escondido, California · 158 sites in all
- A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian CancerPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07213804 · 1,630 participants (planned) · Start Oct 22, 2025 · Primary completion Nov 2028
Drug: Sofetabart Mipitecan; Paclitaxel and 6 more · For: Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms and 1 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Burbank, California · 264 sites in all
- A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT06119581 · 1,264 participants (planned) · Start Dec 21, 2023 · Primary completion Nov 2027
Drug: LY3537982; Pembrolizumab and 4 more · For: Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis
Sites: Huntsville, Alabama; Gilbert, Arizona; Phoenix, Arizona · 415 sites in all
- Efficacy and Safety of Orforglipron in Participants With Peripheral Artery DiseasePivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07223593 · 1,205 participants (planned) · Start Oct 31, 2025 · Primary completion Jun 2028
Drug: Orforglipron; Placebo · For: Peripheral Arterial Disease
Sites: Birmingham, Alabama; Gilbert, Arizona; Surprise, Arizona · 169 sites in all
- A Study of Brenipatide in Participants With Alcohol Use DisorderPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07219953 · 1,100 participants (planned) · Start Oct 16, 2025 · Primary completion Apr 2028
Drug: LY3537031; Placebo · For: Alcohol Use Disorder
Sites: Scottsdale, Arizona; Little Rock, Arkansas; Los Angeles, California · 115 sites in all
- A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use DisorderPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07219966 · 1,100 participants (planned) · Start Oct 15, 2025 · Primary completion Apr 2028
Drug: LY3537031; Placebo · For: Alcohol Use Disorder
Sites: Birmingham, Alabama; Scottsdale, Arizona; Little Rock, Arkansas · 117 sites in all
Marketed drugs (40)
Newest FDA action first.
- Olumiant Baricitinib · 2018
- Jaypirca Pirtobrutinib · 2023
- Onswik Insulin Efsitora Alfa-Gobe · 2026
- Verzenio Abemaciclib · 2017
- Inluriyo Imlunestrant Tosylate · 2025
- Mounjaro Tirzepatide · 2022
- Zepbound Tirzepatide · 2023
- Foundayo Orforglipron Calcium · 2026
- Forteo Teriparatide · 2002
- Retevmo Selpercatinib · 2020
- Retevmo Selpercatinib · 2024
- Ebglyss Lebrikizumab-Lbkz · 2024
- Emgality Galcanezumab-Gnlm · 2018
- Trulicity Dulaglutide · 2014
- Humatrope Somatropin · 1986
- Omvoh Mirikizumab-Mrkz · 2023
- Cyramza Ramucirumab · 2014
- Kisunla Donanemab-Azbt · 2024
- Humalog Kwikpen Insulin Lispro Recombinant · 1996
- Humalog Kwikpen Insulin Lispro Recombinant · 2015
- Taltz Ixekizumab · 2016
- Rezvoglar Insulin Glargine-Aglr · 2022
- Humalog Mix 75/25 Pen Insulin Lispro Protamine Recombinant, Insulin Lispro Recombinant · 1999
- Humalog Mix 50/50 Kwikpen Insulin Lispro Protamine Recombinant, Insulin Lispro Recombinant · 1999
- Lyumjev Insulin Lispro-Aabc · 2020
- Alimta Pemetrexed Disodium · 2004
- Humulin N Insulin Susp Isophane Recombinant Human · 1982
- Humulin 70/30 Pen Insulin Recombinant Human, Insulin Susp Isophane Recombinant Human · 1989
- Humulin R Pen Insulin Recombinant Human, Insulin Human · 1982
- Basaglar Insulin Glargine · 2015
- Adcirca Tadalafil · 2009
- Evista Raloxifene Hydrochloride · 1997
- Verzenio Abemaciclib · 2018
- Cialis Tadalafil · 2003
- Portrazza Necitumumab · 2015
- Cymbalta Duloxetine Hydrochloride · 2010
- Cymbalta Duloxetine Hydrochloride · 2008
- Evista Raloxifene Hydrochloride · 2007
- Cymbalta Duloxetine Hydrochloride · 2004
- Alimta Pemetrexed · 2004
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.